

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 5/00	A2	(11) International Publication Number: WO 99/03878 (43) International Publication Date: 28 January 1999 (28.01.99)
(21) International Application Number: PCT/IT98/00202 (22) International Filing Date: 17 July 1998 (17.07.98) (30) Priority Data: RM97A000441 17 July 1997 (17.07.97) IT (71) Applicants (for all designated States except US): POLIFARMA S.P.A. [IT/IT]; Via di Tor Sapienza, 138, I-00155 Roma (IT). CONSIGLIO NAZIONALE DELLE RICERCHE [-/IT]; Piazzale Aldo Moro 7, I-00185 Roma (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): POLITI, Vincenzo [IT/IT]; Via Albano, 77, I-00179 Roma (IT). GAVUZZO, Enrico [IT/IT]; Via F. Turati, 155, I-00185 Roma (IT). GALLINA, Carlo [IT/IT]; Via Vigevano, 10, I-00161 Roma (IT). DI STAZIO, Giovanni [IT/IT]; Via Clivo di Cinna, 221, I-00136 Roma (IT). D'ALESSIO, Silvana [IT/IT]; Piazza Marchisio, 245, I-00173 Roma (IT). SELLA, Antonio [IT/IT]; Via delle Petunie, 6, I-00171 Roma (IT). PIAZZA, Cinzia [IT/IT]; Via Forte Braschi, 84, I-00167 Roma (IT). GIORDANO, Cesare [IT/IT]; Via Gargallo, 6, I-00137 Roma (IT). GORINI, Barbara [IT/IT]; Piazza Vinci, 19, I-00139 Roma (IT). PANINI, Gabriella [IT/IT]; Via Lavagna, 7, I-00048 Nettuno (IT).		PAGLIALUNGA PARADISI, Mario [IT/IT]; Viale Marx, 319, I-00137 Roma (IT). CIRILLI, Maurizio [IT/IT]; Via P. Romano, 25, I-00169 Roma (IT). POCHETTI, Giorgio [IT/IT]; Via G. Antamoro, 100, I-00139 Roma (IT). MAZZA, Fernando [IT/IT]; Via E. Romagnoli, 3, I-00137 Roma (IT). (74) Agents: BAZZICHELLI, Alfredo et al.; Società Italiana Brevetti S.p.A., Piazza di Pietra, 39, I-00186 Roma (IT). (81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>In English translation (filed in Italian). Without international search report and to be republished upon receipt of that report.</i>
(54) Title: NEW METALLOPROTEINASE INHIBITORS, THEIR THERAPEUTIC USE AND PROCESS FOR THE PRODUCTION OF THE STARTING COMPOUND IN THE SYNTHESIS THEREOF		
(57) Abstract <p>Objects of the present invention are peptido-mimetic compounds having the capacity of acting as inhibitors of metalloproteinases produced by snake venom, and of other metalloproteinases of human origin which have been related with various pathologies in man, including tumoral growth and metastatization, atherosclerosis, multiple sclerosis, Alzheimer's disease, osteoporosis, hypertension, rheumatoid arthritis and other inflammatory diseases. Object of the present invention is also the procedure for the production of diethylester of (1)-phosphotryptophan, as starting product necessary to synthesize all compounds mentioned above.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NEW METALLOPROTEINASE INHIBITORS, THEIR THERAPEUTIC USE
AND PROCESS FOR THE PRODUCTION OF THE STARTING COMPOUND
IN THE SYNTHESIS THEREOF

DESCRIPTION

The present invention has as its object new compounds usable in the therapy of a series of human pathologies such as tumoral growth and metastatization, atherosclerosis, multiple sclerosis, Alzheimer's disease, osteoporosis, rheumatoid arthritis and other inflammatory diseases. Said compounds in fact, following in vitro experiments extensively described in the following chapters, showed a remarkable inhibitory capability on certain human enzymes, the zinc-dependent metalloproteinases, which have been related with such pathologies (see for example: "Inhibition of matrix metalloproteinases. Therapeutic potential" - Annuals N.Y. Acad.Sci. 732 (1994)). Thus although an integration of experimental data with adequate evidence in vitro is naturally necessary, the results collected already allow to expect their usability in specific therapies. Moreover such inhibitory capacity was originally demonstrated also in a series of zinc-dependent metalloproteinases extracted from snake venoms, also denominated "hemorrhagines" for their capacity of inducing extensive internal hemorrhages in victims of snake bites, and constitute the most damaging agent in the venomous mixtures elaborated by Crotalidae and Viperidae. Thus their usability also in preparing specific antidotes against venom of Crotalidae and Viperidae seems evident.

The design and synthesis of such compounds in fact constitutes the last step in a long course of research, based on the study of the structure and action mechanism of certain particular zinc-dependent metalloproteinases called hemorrhagines.

The so-called Hemorrhagic Factors or Hemorrhagines constitute a very important class of enzymes detected in the venom of snakes belonging to the Crotalidae family.

They are structurally of use to the snake as they rapidly induce extended internal hemorrhagies in victims, causing circulatory collapse and preventing the victim from escaping its fate. The mechanism of the hemorrhagic action is due to the particular ease with which the enzymes are capable of degrading a large number of filiform proteins which bind the various vasal endothelial cells, allowing the elements of the blood to escape from the vessels. Although their molecular weights differ greatly, the hemorrhagines maintain however some fixed characteristics on the catalytic site, in the way that Zinc bonds with certain amino acids of the proteic chain, and in the way in which they attack the proteins of the basal membrane of blood vessels. They also seem to have in common the mechanism which ensures the protection of the snake's organism from the toxic effects of its own metalloproteinases, which seems based on the production of tripeptides capable of functioning as competitive inhibitors, interacting with the active site of the enzyme containing Zinc (Biomed.Biochim.Acta 50, 769-773, 1991).

Now the presence of Zinc in the active site of the enzyme constitutes one of the most interesting aspects of the study of Hemorrhagines. In fact this characteristic is not exclusively theirs, but characterizes a wide number of proteolytic enzymes which perform a series of important and diversified physiological and pathological functions in other animal organisms, evolutively also quite distant from each other. In relation to this a comparative study was carried out to determine possible similarities and differences in structure.

By studying the sequences of residues of the proteic chains and the amino acids involved in Zinc bonding it has been possible to obtain a sort of "family tree" for this family of proteinases (see for example FEBS Letters 312, 110-114, 1992 and Developmental Biology 180, 389-401, 1996): it has thus been seen that the active site of

enzymes belonging to living beings quite distant from each other, such as Astatin (extracted from a river crustacean), Seratin (obtained from a microorganism), Matrixines (present in the organism of mammals) and those of Hemorrhage Factors of snake venom, in reality differ only in one of the four amino acids binding Zinc. Thus in spite of the fact that there are strong differences in the rest of the proteic structure, they can be considered to be in some way evolutively correlated. This is particularly interesting when considering the fact that the functions performed by these enzymes are not in any way analogous. In fact it has been ascertained that proteolytic enzymes of snake venom if on one hand are very similar and have thus allowed the definition of a proper new family of proteinases: snake venoms metalloproteinases (see for example Biol.Chem. Hoppe-Seyler 373, 381-385, 1992), on the other hand, they do not show any functional similarity with any other protein of the plant or animal world. In particular an extremely relevant fact is the difference between the functionality of hemorrhagines and those of Human Matrixines, which exercise important effects on cell migration and on the reconstruction of damaged tissues. Moreover, while Matrixines are released in the form of "zimogens" (that is, inactive enzymes which must be made functional through other proteinases intervention), and can be inhibited by particular proteins (TIMP), hemorrhagines are immediately active at the moment of dilution in the blood flow. In spite of such structural and functional differences the Applicant has determined the existence of a close correspondence between the inhibition of snake hemorrhagines and the pharmacological results obtained on animal models in which the pathogenous agent is presumed to be a zinc-dependent metalloproteinase produced by the tissues of the mammal. Such correspondence seems the consequence of a structural resemblance existing albeit only in the active site between two different types of

metalloproteinases and, based on this, the Applicant has developed a method for the selection of compounds for potential therapeutic use in man (Italian patent application RM95A000557; European patent application EP0758021).

Many mammal zinc-dependent metalloproteinases in fact have been related with pathological situations, some of which have been mentioned above. For example gelatinases seem involved in tumoral metastatization, while collagenases have a pathogenic role in arthritic phenomena.

Certain compounds which inhibit matrixines have begun the phases of clinical development in patients suffering from tumour or arthritis: however they are usually scarcely absorbed when administered orally, and are constituted by hydroxamates, compounds which can present toxicity problems in chronic administration.

Finally, a new family of zinc-dependent metalloproteinases was recently identified, localized on the cell membrane, which possess the same proteic domains of hemorrhagines, and are thus considered their closest relatives (see Developmental Biology 180, 389-401, 1996). These proteinases, called ADAM (A Disintegrin and A Metalloproteinase Domain), are correlated with the functionality of the reproductive apparatus, but are also responsible for releasing TNF- α (Tumor Necrosis Factor alfa) and ACE in the circulation and seem correlated to SNC diseases, including Multiple Sclerosis.

SUMMARY OF THE INVENTION

The aim of the present invention is to supply compounds with pharmacological activity towards human pathologies, which have been securely related with the enzymatic activity of zinc-dependent metalloproteinases.

The strategy followed to solve this problem was to take as starting-points the ascertained resemblance in the structure of the active site existing between Hemorrhagines and other mammal zinc-dependent

metalloproteinases, and the mechanism of protection of the snake against the effects of its own venom, based on the production of peptides inhibiting the enzymatic activity of Hemorrhagines themselves.


Based upon these data, the synthesis of new compounds capable of acting as inhibitors of the snake's proteinases was designed, supposing that, given the structural resemblance in the active site, they could also act as inhibitors of human zinc-dependent metalloproteinases.

Therefore, a first step consisted in designing these compounds on the basis of the three-dimensional characteristics of the active site of a Hemorrhagine resolved on X-ray, Adamalysin II, and of the known data concerning the "natural" inhibitors of such enzyme.


In this way in fact it is possible not only to visualize the relative structure of each single domain of the protein, but also to verify the relationship of domains within the quaternary structure of the protein. It is therefore possible to obtain some structural data which together with the enzymatic data offer a significant contribution to the comprehension of the action-inhibition mechanism of a given protein. It has thus been possible to design and build certain compounds potentially capable of binding the active site and of acting as inhibitors of the protein itself.

As an outcome of this phase it has been possible to arrive at a definition of these "peptido-mimetic" compounds, that is, similar to peptides, but lacking at least one of the bonds that make molecules easily attackable by the proteolytic enzymes, with an important characteristic in the substitution of the residue of the terminal tryptophan with the analogous phosphonate.

The compounds according to the present invention can be represented according to the following general formula:





in which R can be H, or $\text{CH}_2\text{-C}_6\text{H}_5$, and R' can be a saturated or aromatic ring formed by five or six members, of which one at least is not carbon, but can be selected among nitrogen, oxygen and sulphur. An example is supplied by the following structures:




Such compounds were then obtained through two different synthesis schemes, confluent into one another in the final phase.

In Diagram 1, diethylester of (1)-phosphotryptophan (1) obtained by using a modified version of the method

described above (Subotkowski, J., Kowalik J., Tyka R., Mastalerz P. *Pol.J.Chem.* 1981, 55, 853-857; Rogers R.S., Stern M.K. *Synlett.* 1992, 708), (i.e., the reduction of 1-hydroxymino-2-(3-indolyl) ethane phosphonate with aluminium amalgam in presence of aqueous ammonia), is reacted with a pseudo-peptide, obtained by acylation of leucin with $R'-COOH$ acid, where R' represents a saturated or aromatic ring, formed by five or six members, of which at least one is not constituted by carbon, but can be selected among nitrogen, oxygen and sulphur. The resulting diethyl esters (3) are thus transformed into the corresponding free phosphonic acids which were isolated, purified and kept as cyclohexylamine salts (4).




In the specific case of compound 5, said compound was obtained and isolated as an inner salt. This occurs also with other saturated rings of 5 or 6 member containing nitrogen.




The conditions under which the aforementioned experiments were carried out are indicated by symbols in the diagram and are the following: (i) DCC, 1-HBT, THF, 15h, 53-73%; (ii) N,O-bis(trimethylsilyl)-acetamide, Me_3SiI , CH_2Cl_2 , 25°C , 2h; (iii) $\text{C}_6\text{H}_{11}\text{NH}_2$, AcOEt , 40-86%; (iv) 10% Pd/C, EtOH, 25°C , 2h, 85%.

In Diagram 2 instead indoleacetic acid (6) is converted into benzyl diethyl-ester (8) of phosphotryptophan.




The compound thus obtained (8) is then reacted with

the pseudo-peptides already used in the synthesis scheme described previously.



The removal of only one of the two benzyl groups produces monobenzylester (10).



The reaction conditions are here too summarily distinguished by symbols and are listed below: (i) ClCO-COCl , CH_2Cl_2 , 0,3%DMF, refl, 30 min; (ii) $\text{Me}_3\text{Si-O-P}(\text{O-CH}_2\text{-C}_6\text{H}_5)_2$, CH_2Cl_2 , -18°C , 1h; (iii) $\text{NH}_2\text{OH HCL}$, $\text{C}_5\text{H}_5\text{N}$, EtOH, from -18 to 4°C , 15 h 46%; (iv) AlHg , NH_4OH , EtOH, 25°C , 2 h, 68%; (v) $\text{R}'\text{-CO-Leu-OH}$, $i\text{-Bu-O-CO-Cl}$, NMM, THF, -20°C , 88%; (vi) AlHg , NH_4OH , EtOH, 25°C , 4 days, 58%.

STUDY OF PHARMACOLOGICAL ACTIVITY

The therapeutic activity of pseudo-peptides thus obtained was verified applying the method previously devised by the Applicant (Italian Patent application

RM95000957) taking into consideration the specific characteristics of the case.

The compounds thus obtained were first subjected to experiments to test their actual capacity of inhibiting enzymatic activity of snake venom metalloproteinases, having been designed on the relative three-dimensional structure of such metalloproteinases, with respect to the capacity of bonding to the enzymes' active site and thus of acting as competitive inhibitors.

This property was verified in particular by inhibition tests *in vitro* on metalloproteinase Adamalysin II purified from *Crotalus Adamanteus* venom, a protein of which the three-dimensional configuration is entirely known, which was also selected because among snake metalloproteinases it is the one closest to human metalloproteinase, due to the remarkable homology of the primary aminoacid sequence which it presents with the enzyme which releases TNF- α in man (TACE) in the active site. The results extensively described in example 5 indicate the existence of a good inhibitory capacity in all tested compounds, some of which show also a remarkable power of action (see *infra* table I). Because of the resemblance between Adamalysin II and TACE, these results are indicative *per se* also of a possible pharmacological activity of the compounds against TNF- α .

The next step consisted therefore in testing the inhibitory capacity of such compounds also in relation to human metalloproteinases. Reference proteinases were significantly selected for this reason as neutrophile Collagenase and purified Gelatinase A from human cell cultures.

Gelatinase A also known as MMP-2, is in fact an enzyme belonging to the Matrixin family which have been shown to be produced in great quantity in many pathological situations, and believed to be primarily responsible for the migration of tumoral cells from the blood towards tissues affected by metastasization phases.

Likewise also neutrophile Collagenasis (denominated MMP8), also belonging to the matrixin family, has been related with a large number of pathological situations. In particular it is considered primarily responsible for the destruction of cartilage which is observed in cases of chronic inflammation. Consequently, it is quite clear that the identification of inhibitors of the activity of both these proteins must be considered a first and important step to elaborate new efficient therapies for these pathologies.

With reference to these considerations, testing has been carried out on neutrophile Collagenasis and Gelatinasis A themselves for assessing the effective synthesized compounds capacity to bond to the active site of human metalloproteinase, and so to act as competitive inhibitors.


The results extensively described in examples 5 and 6 have shown the existence of a good (albeit varying from compound to compound) inhibitory capacity of such compounds also for these metalloproteinases. Also considering the fact that the two proteinases perform functions which are also performed by other matrixines, the results obtained for both must therefore be considered as indicative also of the potential inhibitory capacity of the pseudo-peptides object of the present invention on other zinc-dependent matrixines implicated as pathogenetic agents, in many pathological situations in man.

These capacities are thus indicative of a potential use of pseudo-peptides as powerful therapeutic agents, whose efficacy and pharmacological usefulness is enhanced by their peculiar chemical characteristics.


The modifications of the peptidic structure of these compounds are likely to make them resistant to gastric proteolytic enzymes, and therefore they can be considered suitable for oral administration. Moreover the substitution of the terminal tryptophan residue with the

analogous phosphonate remarkably increases the inhibitory activity on enzymes, without introducing risks of systematic toxicity of molecules presently subjected to clinical testing in tumors and arthritis. In fact they are based on hydroxamate compounds which have great power in bonding zinc, but which after prolonged administration can introduce in the organism an accumulation of hydroxylamin, a potentially cancerogenous agent. The compounds object of the present invention instead, being phosphonates, do not present risks of dangerous side-effects, as is demonstrated by drugs of this category which are on the market now.

With reference to all the above, object of the present invention are compounds of general formula:



in which R can be H, or $\text{CH}_2\text{-C}_6\text{H}_5$, and R' can be a saturated or aromatic ring of five or six members, of which at least one is not carbon, and can be selected among a group including nitrogen, oxygen and sulphur. A particularly preferred case is that in which R' is selected from the group including:



Also object of the present invention is the use of the same as inhibitors of enzymatic activity of at least one of the zinc-dependent metalloproteinases extracted from the venom of snakes belonging to the families of the Crotalidae and of the Viperidae also denominated hemorrhagines (in particular Adamalysin II), and/or at least one of the zinc-dependent metalloproteinases of human origin, of which the active site presents a three-dimensional structure analogous to that of the said snake metalloproteinase (in particular the neutrophilic Collagenase, Gelatinase A and the ADAM).

Consequently to all observations reported so far the use of such compounds as pharmaceuticals for the therapeutic treatment of all human pathologies in which the pathogenic mechanism or in which the symptomatology has been demonstrated to include at least one zinc-dependent metalloproteinase, and relative pharmaceutical compounds containing them must also be considered. In particular, reference is made to tumoral growth and metastasization, atherosclerosis, multiple sclerosis, Alzheimer's disease, osteoporosis, hypertension, rheumatoid arthritis, and other inflammatory diseases.

A further object of the present invention is the process for producing the (1)-phosphotryptophan diester as the starting product for the synthesis of the compounds previously described, including as an essential operation the reduction of 1-hydroxymino-2-(3-indolyl) ethane phosphonate by adding an amalgam of aluminium in presence of aqueous ammonia.

A general description of the present invention has been made so far. With the aid of the following examples, a more detailed description of specific embodiments will now be given, in order to give a better understanding of the objects, characteristics, advantages and operating methods of the invention. Such examples serve merely to illustrate and do not limit the scope of the present invention.

Example 1

Preparation of oxalate of (1)-diethyl-1-amino-2-(3-indolyl) ethane phosphonate (Compound 1)

To a solution of diethyl-1-hydroxymino-2-(3-indolyl)ethane phosphonate (Subotkowski, J., Kowalik J., Tyka R., Mastalerz P. *Pol. J. Chem.* 1981, 55, 853-857) (7.93 g, 25.6 mmols) in EtOH/H₂O 13/1 (38 ml) and aqueous NH₃ at 25% (11 ml), under stirring, an amalgam of aluminium (15 g) was added. After 19 hours at room temperature the reaction mixture was filtered on kieselguhr and the solution was concentrated at reduced pressure. The raw product was dissolved in EtOAc (500 ml) and extracted with NaOH 1N (100 ml) and NaCl saturated solution (100 ml). After drying the organic phase on Na₂SO₄, the solvent was removed at a reduced pressure. The raw product was dissolved in EtOAc (40 ml) under stirring, and added dropwise with a solution of oxalic acid (2.30 g, 25.6 mmols) in EtOAc (40 ml). The salt formed as a crystalline hygroscopic solid was recovered by filtration: 9.88 g (100%).

The (1)-diethyl-1-amino-2-(3-indolyl) ethane phosphonate (1) used in the subsequent transformations

was obtained by separation from the racemic form by employing D-(+)-dibenzyltartaric acid (Lavielle G., Hauteffaye P, Schaeffer C., Boutin J. A., Cudennec C.A., Pierré A. *J. Med. Chem.* 1991, 34, 1998-2003).

Example 2

Preparation of the pseudo-dipeptides

Preparation of N-[(furan-2-yl)carbonyl]-L-leucine (Compound 2a)

To a solution of furan-2-carboxylic acid (2.0 g, 17.8 mmols) and N-methylmorpholine (1.95 ml, 17.8 mmols) in anhydrous THF (10 ml), cooled at -15°C was added dropwise under stirring an equivalent quantity of isobutylchloroformate (2.33 ml, 17.8 mmols). After 30 minutes a solution of L-leucine methylester hydrochloride (3.23 g, 17.8 mmols) and N-methylmorpholine (1.95 ml, 17.7 mmols) in anhydrous THF (15 ml) was slowly added, maintaining the mixture under stirring at -15°C for two hours. The reaction mixture was diluted with CH₂Cl₂ (100 ml) and washed with HCl 1N (30 ml x 2), NaHCO₃ saturated solution (30 ml x 2), and NaCl saturated solution (30 ml). After drying the organic phase on Na₂SO₄ and removal of the solvent at a reduced pressure, the raw product was obtained as an oily residue which spontaneously solidified. By grinding the solid substance in petroleum ether, white crystals of ether N-[(furan-2-yl)carbonyl]-L-leucine methylester were obtained: 3.32 g (80%); m.p. 88-90°C; [α]_D²² = -23°C (1, methanol); IR (CHCl₃): 3424, 2956, 1741, 1663, 1595, 1517, 1351, 1177 cm⁻¹; ¹H-NMR (CDCl₃): δ 0.95 and 1.02 [two s, 6, CH₂CH(CH₃)₂], 1.45-2.00 [m, 3, CH₂CH(CH₃)₂], 3.85 (s, 3, OCH₃), 4.73-5.13 (m, 1, aCH), 6.39-7.45 [m, 3, furan aromatics and 6.89 (d, 1, NH, J=8Hz)]. Calculated for C₁₂H₁₇NO₄: C, 60.24; H 7.16; N 5.85. Found C 60.15; H 7.22; N 5.88%.

A solution of N-[(furan-2-yl)carbonyl]-L-leucine methylester (2.73 g, 11.4 mmols) and dioxane/MeOH 7/1 (80 ml) and NaOH 1N (22.8 ml) was kept at room temperature for one night. After concentrating the solvent at reduced

pressure the alkali aqueous phase was diluted in H₂O (20 ml), washed with Et₂O (30 ml x 2), acidified with HCl 2N and extracted with CHCl₃ (70 + 30 ml). The organic phases were washed with NaCl saturated solution (30 ml x 2), dried on Na₂SO₄ and evaporated at reduced pressure. The crystallization of the raw product from CH₂Cl₃/petroleum ether has provided the pure product (2a) in white solid form: 2.24 g (90%); m.p. 80-3°C; [α]_D²² = -10°C (1, methanol); IR (CHCl₃): 3426, 2957, 1721, 1659, 1593, 1419, 1179, 1011 cm⁻¹; ¹H-NMR (MeOD): δ 0.75-1.08 [m, 6, CH₂CH(CH₃)₂], 1.50-1.83 [m, 3, CH₂CH(CH₃)₂], 4.32-4.80 (m, 1, aCH), 6.30-7.46 (m, 4, furan protons). Calculated for C₁₁H₁₅NO₄: C, 58.66; H, 6.71; N, 6.22. Found C, 58.34; H, 6.33; N, 6.01%.

Preparation of N-[(pyrrol-2-yl)carbonyl]-L-leucine (Compound 2b).

To a solution of pyrrol-2-carboxylic acid (1.11 g, 10 mmols), L-leucine methylester hydrochloride (1.82 g, 10 mmols) and N-methylmorpholine (1.09 ml, 10 mmols) in EtOAc (25 ml), cooled at 0°C, was added under stirring, a solution of DCDI (2.06 g, 10 mmols) and HBT (13 mg, 1 mmols) in EtOAc (5ml). After standing for one night at room temperature, the N,N'-dicyclohexylurea and the N-methylmorpholine hydrochloride were separated by filtration.

The reaction mixture was then diluted with 100 ml of EtOAc and extracted with HCl 1N (40 + 20 ml), NaHCO₃ saturated solution (40 + 20 ml) and NaCl saturated solution (40 ml). After drying of the organic phases reunited on Na₂SO₄, the solvent was eliminated at reduced pressure. The crystallization of raw material from sim-dichloroethane/n-hexane gave N-[(pyrrol-2-yl)carbonyl]-L-leucine methylester as a light pink solid: 1.73 g (73%); m.p. 131-2°C; [α]_D²² = -13°C (1, methanol); IR (CHCl₃): 3450, 2956, 1737, 1642, 1553, 1551, 1179, 1113 cm⁻¹; ¹H-nmr (CDCl₃): δ 0.88 and 0.95 [two s, 6, CH₂CH(CH₃)₂], 1.47-1.80 [m, 3, CH₂CH(CH₃)₂], 3.62 (s, 3, OCH₃), 4.50-

4.82 4M, 1, ACH7, 5.87-6.75 (m, 4, pyrrol aromatics and NH), 9.92 (bs, 1, pyrrol NH). Anal. Calculated for $C_{12}H_{18}N_2O_3$: C, 60.49, H, 7.61; N, 11.76. Found C, 60.72; H, 7.82; N, 11.87%.

A solution of N-[(pyrrol-2-yl)carbonyl]-L-leucine methylester (1.82 g, 7.62 mmols) in dioxane/MeOH 7/1 (80 ml) and NaOH 1N (15.24 ml) was kept at room temperature for one night. After concentrating the solvent at reduced pressure the alkali aqueous phase was diluted in H_2O (15 ml), washed with Et_2O (25 ml x 2), acidified with HCl 2N and extracted with $CHCl_3$ (60 + 20 ml). The organic phases were washed with NaCl saturated solution (20 ml x 2), dried on Na_2SO_4 and evaporated at reduced pressure. The crystallization of the raw product from sim-dichloroethane provides the pure product (2b) as white crystals: 708 mg (41%); m.p. 78-80°C; $[a]_D^{22} = -8^\circ$ (1, acetonitrile); IR ($CHCl_3$): 3448, 3262, 2957, 1713, 1640, 1553, 1437, 1185, 1042, cm^{-1} ; 1H -NMR ($CDCl_3$): δ 0.75-1.05 [m, 6, $CH_2CH(CH_3)_2$], 1.40-1.85 [m, 3, $CH_2CH(CH_3)_2$], 4.07-4.48 (m, 1, aCH), 5.78-6.72 (m, 3, pyrrol aromatics), 7.75 (d, 1, NH, $J = 4.5$ Hz), 8.0 (s, 1, NH of pyrrol), 10.59 (bs, 1, COOH). Calculated. per $C_{11}H_{16}N_2O_3$: C, 58.91; H, 7.19; N, 12.49. Found C, 58.53; H, 7.18; N 12.20%.

Preparation of N-[(S)-(5-oxo-tetrahydrofuran-2-yl)carbonyl]-L-leucine (Compound 2e).

To a solution of (S)-(+)-5-oxo-tetrahydrofuran-2-carboxylic acid (1.0 g, 7.68 mmols) and N-methylmorpholine (0.84 ml, 7.68 mmols) in anhydrous/THF anhydrous dioxan 2/1 (15 ml), cooled at -15°C was added dropwise, under stirring, the equivalent quantity of isobutylchloroformate (1.04 ml, 7.68 mmols). After 30 minutes a solution of L-leucine tertbutylester (1.44 g, 7.68 mmols) and anhydrous THF (5 ml) was slowly added, maintaining the mixture under stirring at -15°C for two hours. The reaction mixture was diluted with CH_2Cl_2 (70 ml) and washed with NaCl saturated solution (20 ml) $KHSO_4$ 1M (20 + 10 ml), $NaHCO_3$ saturated solution (20 + 10 ml)

and NaCl saturated solution (20 ml). The organic phase was dried on Na₂SO₄ and concentrated at reduced pressure. The raw product was purified through chromatography on silica gel (CH₂Cl₂/*i*-PrOH 98/2). By grinding in *n*-hexane the solid raw residue, the N-{[(S)-(5-Oxo-tetrahydrofuran-2-yl)carbonyl]}-L-leucine tertbutyl-ester was obtained as white crystals: 920 mg (40%); m.p. 79-81°C; [α]_D²² = -25° (1, methanol); IR (CHCl₃): 3415, 2934, 1788, 1727, 1677, 1517, 1369, 1149 cm⁻¹; ¹H-NMR (CDCl₃): δ 0.87 and 0.97 [two s, 6, CH₂CH(CH₃)₂], 1.18-1.62 [m, 3, CH₂CH(CH₃)₂] and 1.40 (s, 9, C(CH₃)₃), 2.15-2.80 (m, 4, ring CH₂CH₂), 4.25-4.55 (m, 1, ring CH), 4.62-4.88 (m, 1, aCH), 6.56 (d, 1, NH, J=8 Hz). Calculated for C₁₅H₂₅NO₅: C, 60.18; H, 8.42; N, 4.68. Found C, 60.12; H, 8.61; N, 4.65%.

To a solution of N-{[(S)-(5-Oxo-tetrahydrofuran-2-yl)carbonyl]}-L-leucine tertbutylester (800 mg, 2.67 mmols) in CH₂Cl₂ (3.0 ml) cooled at 0°C, was added freshly distilled anhydrous trifluoroacetic acid (0.5 ml). After a night at room temperature the solvent was evaporated at reduced pressure and the residue was dissolved in Et₂O. By adding *n*-hexane the compound (2e) separated as a brown oil and was dried and decanted in high vacuum: 650 mg (100%); [α]_D²² = -7° (1, methanol); IR (CHCl₃): 3413, 3036, 2957, 1787, 1725, 1678, 1526, 1172, 1151 cm⁻¹; ¹H-NMR (CDCl₃): δ 0.87 and 0.93 [two s, 6, CH₂CH(CH₃)₂], 1.37-1.83 [m, 3, CH₂CH(CH₃)₂], 2.06-2.73 (m, 4, ring CH₂CH₂), 4.30-4.63 (m, 1, ring CH), 4.67-4.92 (m, 1, aCH), 6.92 (d, 1, NH, J=8 Hz), 8.15 (s, 1, COOH). Calculated for C₁₇H₃₀N₂O₅·1/2 H₂O (cyclohexylamine salt): C, 56.66; H, 8.89; N, 7.77. Found C, 57.00; H, 9.12; N 8.13%.

Preparation of N-{[(R)-(2-oxo-thiazolidine-4-yl)carbonyl]}-L-leucine (Compound 2f).

To a solution of (R)-(-)-2-oxo-thiazolidine-4-carboxylic acid (1.49 g, 10.2 mmols), L-leucine methylester hydrochloride (1.85 g, 10.2 mmols) and N-

methylester (1.12 ml, 10.2 mmols) in anhydrous THF (15 ml), cooled at 0°C, was added, under stirring, a solution of DCDI (2.10 g, 10.2 mmols) and HBT (13 mg, 1 mmols) in anhydrous THF (8 ml). After standing one night at room temperature, the N,N'-dicyclohexylurea and the hydrochloride of N-methylester were separated by filtration and the filtered substance was concentrated at reduced pressure. The product was purified by dilution of the raw residue with CHCl₃ (50 ml) and extraction with saturated NaHCO₃ solution (20 ml x 2) and saturated NaCl solution (30 ml). Drying of the organic phases reunited on Na₂SO₄ and the removal of the solvent at reduced pressure provided the N-[(R)-(2-Oxo-thiazolidine-4-yl)carbonyl]-L-leucine methylester which was crystallized with EtOAc: 1.94 g (69%); m.p. 125-6°C; [α]_D²² = -79° (1, methanol); IR (CHCl₃): 3412, 2956, 1734, 1678, 1515, 1434, 1338, 1158 cm⁻¹; ¹H-NMR (CDCl₃): δ 0.90 and 0.95 [two s, 6, CH₂CH(CH₃)₂], 1.42-1.74 [m, 3, CH₂CH(CH₃)₂], 3.37-3.85 [m, 2, CH₂S and 3.63 (s, 3, OCH₃)], 4.18-4.69 (two m, 2, aCH and ring CH), 7.16 (d, 1, NH, J=8 Hz). Calculated for C₁₁H₁₇N₂O₄S: C, 48.34; H, 6.27; N, 10.25. Found C, 48.29; H, 6.80; N, 10.22%.

A solution of N-[(R)-(2-Oxo-thiazolidine-4-yl)carbonyl]-L-leucine methylester (2.08g, 7.58 mmols) in dioxane/MeOH 7/1 (90 ml) and NaOH 1N (23 ml) was kept at room temperature for 6 hours. After concentrating the solvent in aqueous alkaline phase it was diluted with H₂O (20 ml), washed with Et₂O (30 ml x 2), acidified with HCl 2N and extracted with EtOAc (70 + 30 ml). The organic phases were washed with saturated NaCl solution (20 ml x 2), dried on Na₂SO₄ and evaporated at reduced pressure. By crystallization of EtOAc the pure product was obtained (2f) as white crystals: 643 mg (32%); m.p. 90-3°C; [α]_D²² = -69° (1, methanol); IR (CHCl₃): 3297, 1672, 1446, 1405, 1369, 1157 cm⁻¹; ¹H-NMR (DMSO-d₆): δ 0.70-0.97 [m, 6, CH₂CH(CH₃)₂], 1.35-1.76 [m, 3, CH₂CH(CH₃)₂], 3.09-3.68 (m, 2, CH₂S), 3.95-4.30 (m, 2, aCH and ring CH), 7.85-

8.07 (m, 2, 2NH). Calculated per $C_{10}H_{16}N_2O_4S$: C, 46.14; H, 6.20; N, 10.76. Found C, 45.75; H, 6.16; N, 10.36%.

Preparation of N-benzyloxycarbonyl-L-pyroglutamyl-L-leucine (Compound 2g).

To a solution of N-benzyloxycarbonyl-L-pyroglutamic acid (1.6 g, 6.0 mmols) and N-methylmorpholine (0.66 ml, 6.0 mmols) in anhydrous THF (10 ml), cooled at -15°C was added dropwise under stirring an equivalent quantity of isobutylchloroformate (0.82 ml, 6.0 mmols). After 30 minutes a solution of L-leucine tertbutylester hydrochloride (1.34 g, 6.0 mmols) and N-methylmorpholine (0.66 ml, 6.0 mmols) in anhydrous THF (9 ml) was slowly added maintaining the temperature at -15°C for 2 hours. The reaction mixture was diluted with EtOAc (70 ml) and washed with saturated NaCl solution (20 ml), KHSO_4 1M (20 + 10 ml), saturated NaHCO_3 solution (20 + 10 ml) and saturated NaCl solution (20 ml). The organic phase was dried on Na_2SO_4 and the solvent was removed at reduced pressure. The crystallization of raw material from EtOAc/n-hexane gave N-benzyloxycarbonyl-L-pyroglutamyl-L-leucine tertbutylester as white crystals: 2.0 g (77%); m.p. $130-1^{\circ}\text{C}$; $[\alpha]_D^{22} = -70^{\circ}$ (1, methanol); IR (CHCl_3): 3420, 2958, 1794, 1723, 1514, 1303, 1152 cm^{-1} ; $^1\text{H-NMR}$ (CDCl_3): δ 0.8-0.91 [m, 6, $\text{CH}_2\text{CH}(\text{CH}_3)_2$], 1.20-1.67 [m, 3, $\text{CH}_2\text{CH}(\text{CH}_3)_2$ and 1.43 (s, 9, $\text{OC}(\text{CH}_3)_3$], 2.00-2.93 (m, 4, CH_2CH_2 of pGlu), 4.27-4.61 (m, 2, 2 aCH), 5.22 (s, 2, CH_2 benzylico), 6.24 (d, 1, NH, $J=8$ Hz), 7.28 (s, 5, benzylic aromatics). Calculated for $\text{C}_{23}\text{H}_{32}\text{N}_2\text{O}_6$: C, 63.87; H, 7.46; N, 6.48; Found C, 64.20; H, 7.60; N, 6.48%.

A solution of N-benzyloxycarbonyl-L-pyroglutamyl-L-leucine tertbutylester (1.0 g, 2.3 mmols) in freshly distilled anhydrous trifluoroacetic acid (3 ml), was kept at 0°C for 30 minutes and for 4 hours at room temperature. Excess trifluoroacetic acid was removed at reduced pressure and the raw product was dried under high vacuum for 2 hours. The crystallization of EtOAc/ Et_2O gave a pure product (2g) as a white solid: 721 mg (83 %);

m.p. 164-5°C; $[\alpha]_D^{22} = -45^\circ$ (1, methanol); IR (KBr): 3336, 3094, 1767, 1654, 1554, 1305, 1288, 1267, 1197, 1153 cm^{-1} ; $^1\text{H-NMR}$ (MeOD): d 0.75-1.02 [m, 6, $\text{CH}_2\text{CH}(\text{CH}_3)_2$], 1.42-1.77 [m, 3, $\text{CH}_2\text{CH}(\text{CH}_3)_2$], 2.00-2.73 (m, 4, CH_2CH_2 of pGlu), 4.29- 4.77 (two s, 2, 2 aCH), 5.23 (d, 2, benzylic CH_2 , $J = 3$ Hz), 7.36 (s, 5, aromatics). Calculated per $\text{C}_{19}\text{H}_{24}\text{N}_2\text{O}_6$: C, 60.63; H, 6.43; N, 7.44. Found C, 60.38; H, 6.09; N, 7.27%.

Example 3:

Acylation of (l)-phosphotryptophan diethylester and preparation of cyclohexylamine salts of the acyl-L-leucyl derivatives of d(l)-phosphotryptophan. General procedure.

A) To a solution of the required L-leucyl derivative (1 mmols) and of (l)-phosphotryptophan diethylester (1 mmols) in anhydrous THF (5 ml) cooled at 0°C, under stirring, is added a solution of DCDI (206 mg, 1 mmols) and HBT (14 mg, 0.1 mmols) in anhydrous THF (5 ml). After resting one night at room temperature the N,N'-dicyclohexylurea is separated by filtration and is concentrated at reduced pressure. The solution of the residue in 30 ml di EtOAc, is extracted with saturated NaHCO_3 solution (20 x 2 ml) and saturated NaCl solution (15 ml). After drying on Na_2SO_4 of the reunited organic phases, the solvent is removed at reduced pressure.

B) To a solution of acyl-L-leucyl-(l)-phosphotryptophan diethylester (1 mmols) in anhydrous CH_2Cl_2 (10 ml), under stirring, in nitrogen atmosphere, an excess of N,O-bis(trimethylsilyl)acetamide (BSA) (11 mmols, 2.69 ml) is added. After 1 hour at room temperature the reaction mixture is cooled at -20°C and an excess of iodotrimethylsilane (8 mmols, 1.1 ml) is added dropwise. At the end of the addition of the reactive substance the solution is brought to 0°C within an hour and maintained at room temperature for other 2 hours. The dark oily residue, obtained through concentration at low pressure of the reaction mixture, is treated with $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ 7/3 (3 ml) for 1 hour. After

removing the solvent at reduced pressure the oily residue is dissolved in EtOAc (40 ml) and washed with Na₂SO₄ 1.5% in HCl 1N (10 ml x 2) and saturated NaCl solution (10 ml). The organic phase is dried on Na₂SO₄ and the solvent is removed at reduced pressure. The raw product, dissolved in EtOAc (4.5 ml), is treated dropwise with a solution of cyclohexylamine (1 mmols) in EtOAc (4.5 ml). Having taken the form of a solid hygroscopic crystal the salt is recovered by filtration.

Preparation of N-[(furan-2-yl)carbonyl]-L-leucyl-(1)-phosphotryptophan salt of cyclohexyl-amine (Compound 4a).

N-[(Furan-2-yl)carbonyl]-L-leucyne (2a, 536 mg, 2.38 mmols) and (1)-phosphotryptophan diethylester (705 mg, 2.38 mmols) were reacted according to procedure A. The raw product was purified by chromatography on silica gel (CHCl₃/i-PrOH 98/2), obtaining the N-[(furan-2-yl)carbonyl]-L-leucyne-(1)-phosphotryptophan diethylester (3a) in the form of foam: 733 mg (62%); $[\alpha]_D^{22} = -55^\circ$ (1, methanol); IR (CHCl₃): 3478, 3418, 1660, 1474, 1244, 1026 cm⁻¹; ¹H-NMR (CDCl₃): d 0.88 [(2d, 6, CH₂CH(CH₃)₂, J= 6.1 Hz], 1.20-1.40 [m, 8, CH₃CH₂O and 2 di CH₂CH(CH₃)₂], 1.60 [m, 1, 1 di CH₂CH(CH₃)₂], 3.11 and 3.35 (two m, 2, bCH₂ Trp^P), 4.12 (m, 4, 2CH₃CH₂O), 4.64 (m, 1, aCH Leu), 4.77 (m, 1, aCH Trp^P), 6.56 (d, 1, NH Leu, J= 8.8Hz), 6.90 (d, 1, NH-CO Trp^P), 6.48-7.61 (m, 8, 5 aromatics of indole and 3 aromatics of furan), 8.10 (s, 1, NH of the indole). Calculated for C₂₅H₃₄N₃O₆P.2/3 H₂O: C, 58.85; H, 6.98; N, 8.24. Found C, 58.40; H, 6.66; N, 7.85%.

N-[(Furan-2-yl)carbonyl]-L-leucyne-(1)-phosphotryptophan diethylester (3a, 150 mg, 0.298 mmols), BSA (0.80 ml, 3.27 mmols) and TMSI (0.32 ml, 2.38 mmols) were reacted according to procedure B. By means of treatment with cyclohexylamine (29 mg, 0.298 mmols) the pure product is obtained (4a) as a hygroscopic solid: 128 mg (79%); $[\alpha]_D^{22} = -67^\circ$ (1, methanol); IR (KBr) 3291, 2937, 1631, 1528 cm⁻¹; ¹H-NMR (DMSO-d₆): d 0.80 [m, 6,

$\text{CH}_2\text{CH}(\text{CH}_3)_2$], 0.95-2.01 [m, 13, $(\text{CH}_2)_5$ cyclohexylamine and $\text{CH}_2\text{CH}(\text{CH}_3)_2$], 2.83 (m, 2, CHN cyclohexylamine and 1H of bCH_2 Trp^P), 3.29 (m, 1, 1H of bCH_2 Trp^P), 4.13 (m, 1, aCH Trp^P), 4.47 (m, 1, aCH Leu) 6.51-7.88 [(m, 9, aromatics of indole, of furan and 7.74 (d, 1, $J = 9.3$ Hz, NH of Trp^P)], 8.48 (d, 1, $J = 8.9$ Hz, NH Leu), 10.64 (s, 1, NH of indole). Calculated $\text{C}_{27}\text{H}_{39}\text{N}_4\text{O}_6\text{P} \cdot 1/2 \text{H}_2\text{O}$ (cyclohexylamine salt): C, 58.37; H, 7.26; N, 10.08. Found C, 58.11; H, 6.99; N, 9.81%.

Preparation of *N*-[(pyrrol-2-yl)carbonyl]-*L*-leucyl-(1)-phosphotryptophan (compound 4b).

N-[(Pyrrol-2-yl)carbonyl]-*L*-leucine (2b, 303 mg, 1.35 mmols) and (1)-phosphotryptophan diethyl ester (400 mg, 1.35 mmols) were reacted according to procedure A. The raw product was purified by chromatography on silica gel ($\text{CHCl}_3/i\text{-PrOH}$ 99/1). Through subsequent grinding in anhydrous Et_2O of the solid residue the *N*-[(Pyrrol-2-yl)carbonyl]-*L*-leucyl-(1)-phosphotryptophan (3b) was obtained as white crystals: 415 mg (61%); m.p. 172-4°C; $[\alpha]_{\text{D}}^{22} = -68^\circ$ (1, methanol); IR (CHCl_3) 3278, 2957, 1632, 1553, 1510, 1332, 1199 cm^{-1} ; $^1\text{H-NMR}$ (CDCl_3): d 0.80 and 0.87 [two s, 6, $\text{CH}_2\text{CH}(\text{CH}_3)_2$], 1.13-1.83 [m, 8, $2\text{CH}_3\text{CH}_2\text{O}$ and two $\text{CH}_2\text{CH}(\text{CH}_3)_2$], 2.59 and 3.27 (two m, 2, bCH_2 Trp^P), 3.79-4.26 (m, 4, $2\text{CH}_3\text{CH}_2\text{O}$), 4.40-5.23 (two m, 2, 2 aCH), 5.83-6.41 (m, 4, pyrrol aromatics and 1 NH), 6.55-7.55 (m, 5, indole aromatics), 8.44 and 8.54 (two s, 2, NH of pyrrol and NH of indole). Calculated for $\text{C}_{25}\text{H}_{35}\text{N}_4\text{O}_5\text{P}$: C, 59.75; H, 7.02; N, 11.15. Found C, 59.47; H, 6.93; N, 10.77%.

N-[(Pyrrol-2-yl)carbonyl]-*L*-leucyl-(1)-phosphotryptophan diethylester (3b, 361 mg, 0.72 mmols), BSA (1.93 ml, 7.92 mmols) and TMSI (0.78 ml, 5.76 mmols) were reacted according to procedure B. Through treatment with cyclohexylamine (71.4 mg, 0.72 mmols) the pure product is obtained (4b) as a hygroscopic solid: 339 mg (86%); $[\alpha]_{\text{D}}^{22} = -74^\circ$ (1, methanol); IR (KBr) 3277, 2937, 1645, 1524, 1140 1047 cm^{-1} ; $^1\text{H-NMR}$ (DMSO-d_6): d 0.80 [m,

6, CH₂CH(CH₃)₂], 0.96-2.00 [m, 13, (CH₂)₅ cyclohexylamine and CH₂CH(CH₃)₂], 2.86 (m, 2, CHN cyclohexylamine and 1H of bCH₂ Trp^P), 3.30 (m, 1, 1H of bCH₂ Trp^P), 4.17 (m, 1, aCH Trp^P), 4.51 (m, 1, aCH Leu) 6.07 (apparent s, 1, CH of pyrrol), 6.75-7.60 [(m, 7, indole aromatics and of pyrrol), 7.72 (d, 1, J= 8.0 Hz, NH of Trp^P)], 8.37 (d, 1, J= 7.7 Hz, NH Leu), 10.67 (s, 1, NH of indole), 12.01 (s, 1, NH of pyrrol). Calculated for C₂₇H₄₀N₅O₅P.7/2 H₂O (cyclohexylamine salt): C, 53.29; H, 7.72; N, 11.51. Found C, 53.37; H, 7.32; N, 11.41%.

L-Prolyl-*L*-leucyl-(1)-phosphotryptophan (Compound 5).

N-Benzyloxycarbonyl-*L*-prolyl-*L*-leucine (Cash W. D. *J.Org.Chem.*, 1961, 26, 2136), (2c 490 mg, 1.35 mmols) and (1)-phosphotryptophan diethylester (400 mg, 1.35 mmols) were reacted according to procedure A. The crystallization of the raw material from anhydrous Et₂O provided the N-benzyloxycarbonyl-*L*-prolyl-*L*-leucyl-(1)-phosphotryptophan diethylester (3c) as a crystal hygroscopic solid: 570 mg (66%); [α]_D²² = -72° (1, methanol); IR (CHCl₃): 3477, 2991, 1687, 1500, 1357, 1217, 1052 cm⁻¹; ¹H-NMR (CDCl₃): d 0.78 and 0.82 [two s, 6, CH₂CH(CH₃)₂], 1.10-1.39 [m, 9, 2CH₃CH₂O and CH₂CH(CH₃)₂], 1.42-2.05 (m, 4, b,g CH₂ of Pro), 2.81-3.50 (m, 4, CH₂N of Pro and bCH₂ of Trp^P), 3.80-4.48 (m, 7, 2CH₃CH₂O and 3 aCH), 4.98 (s, 2, benzylic CH₂), 6.34-7.50 [m, 5, indole aromatic and 7.10 (5, s, benzyl aromatics)], 8.48 (s, 1, NH of indole). Calculated C₃₃H₄₅N₄O₇P.2/3 H₂O: C, 60.79; H, 7.06; N, 8.59. Found C, 60.47; H, 6.90; N, 8.55%.

N-Benzyloxycarbonyl-*L*-prolyl-*L*-leucyl-(1)-phosphotryptophan diethylester (3c, 550 mg, 0.86 mmols), BSA (2.3 ml, 9.46 mmols) and TMSI (0.93 ml, 6.88 mmols) were reacted according to procedure B. After treatment with CH₃CN/H₂O and removal of solvent at reduced pressure, the solid residue was washed with EtOAc and purified with HPLC (Waters ODS DeltaPack 19 x 30 mm

column; eluent H₂O/CH₃CN 70:30; flux 8 ml/minute; retention time: 10,34 min), obtaining 200 mg of pure product (5) in the form of a crystal hygroscopic solid (40%); $[\alpha]_D^{22} = -97^\circ$ (1, NaOH 1N); IR (KBr) 3337, 3262, 2959, 1642, 1135 1071 cm⁻¹; Calculated for C₂₁H₃₁N₄O₅P.2 H₂O: C, 51.80; H, 7.19; N 11.51. Found C, 51.70; H, 6.96; N, 10.88%.

Preparation of N- $\{[(S)-(5\text{-oxo-tetrahydrofuran-2-yl})\text{carbonyl}]\}$ -L-leucyl-(1)-phospho-tryptophan cyclohexylamine salt (Compound 4e)

N- $\{[(S)-(5\text{-Oxo-tetrahydrofuran-2-yl})\text{carbonyl}]\}$ -L-leucine (328 mg, 1.35 mmols) and (1)-phosphotryptophan diethylester (400 mg, 1.35 mmols) were reacted according to procedure A. The purification of the raw material through chromatography on silica gel (CHCl₃/i-PrOH 95/5) and crystallization from Et₂O petroleum ether provided the N- $\{[(S)-(5\text{-oxo-tetrahydrofuran-2-yl})\text{carbonyl}]\}$ -L-leucyl-(1)-phosphotryptophan diethylester (3e) in hygroscopic solid form: 474 mg (68%); $[\alpha]_D^{22} = -48^\circ$ (1, methanol); IR (CHCl₃): 3476, 2992, 1788, 1676, 1517, 1246, 1052 cm⁻¹; ¹H-NMR (CDCl₃): d 0.77 and 0.85 [two s, 6, CH₂CH(CH₃)₂], 1.10-1.60 [m, 9, 2CH₃CH₂O and CH₂CH(CH₃)₂], 2.04-2.48 (m, 4, CH₂CH₂ of the tetrahydrofuran ring), 3.08-3.43 (m, 2, bCH₂ of Trp^P), 3.98-5.00 (m, 7, 2 of CH₃CH₂O, 2 aCH and CH of the tetrahydrofuran ring), 6.76 (d, 1, NH, J=9,8 Hz), 6.95-7.75 (m, 5, indole aromatics), 8.88 (s, 1, NH of indole). Calculated for C₂₅H₃₆N₃O₇P.2/3 H₂O: C, 56.28; H, 7.05; N, 7.88. Found C, 55.92; H, 6.83; N, 7.78%.

N- $\{[(S)-(5\text{-oxo-tetrahydrofuran-2-yl})\text{carbonyl}]\}$ -L-leucyl-(1)-phosphotryptophan diethylester (3e, 207 mg, 0.40 mmols), BSA (1.10 ml, 4.36 mmols) and TMSI (0.43 ml, 3.2 mmols) were reacted according to procedure B. Through treatment with cyclohexylamine (34 mg, 0.40 mmols) pure product is obtained (4e) as a hygroscopic solid: 157 mg (82%); $[\alpha]_D^{22} = -63^\circ$ (1, methanol); IR (KBr) 3280, 2934, 1777, 1641, 1552, 1177, 1048 cm⁻¹; ¹H-NMR (DMSO-d₆): d

0.77 [m, 6, $\text{CH}_2\text{CH}(\text{CH}_3)_2$], 0.95-2.50 [m, 17, $(\text{CH}_2)_5$ della cyclohexylamine, $\text{CH}_2\text{CH}(\text{CH}_3)_2$ and CH_2CH_2 of the tetrahydrofuran ring], 2.87 (bs, 2, CHN cyclohexylamine and 1H of $\text{bCH}_2 \text{Trp}^P$), 3.24 (bs, 1, 1H of $\text{bCH}_2 \text{Trp}^P$), 4.27 (bs, 2, aCH Trp^P and aCH Leu), 4.96 (bs, 1, CH of the tetrahydrofuran ring), 6.79-7.60 (m, 5, indole aromatics), 7.77 (bs, 1, NH Trp^P), 8.91 (bs, 1, NH Leu), 10.55-10.78 (m, 2, NH of indole and NHCHO). Calculated for $\text{C}_{27}\text{H}_{45}\text{N}_4\text{O}_9\text{P} \cdot 2 \text{H}_2\text{O}$ (cyclohexylamine salt): C, 54.17; H, 7.24; N, 9.36. Found C, 54.22; H, 7.57; N, 9.03%.

Preparation of the N- $\{[(R)-(2\text{-oxo-thiazolidin-4-yl})\text{carbonyl}]\}$ -L-leucyl-(1)-phosphotryptophan cyclohexylamine salt (Compound 4f).

N- $\{[(R)-(2\text{-Oxo-thiazolidin-4-yl})\text{carbonyl}]\}$ -L-leucine (2f, 353 mg, 1.35 mmols) and (1)-phosphotryptophan diethylester (400 mg, 1.35 mmols) were reacted according to procedure A. The purification of the raw product through chromatography on silica gel ($\text{CHCl}_3/i\text{-PrOH}$ 95/5) and crystallization from $\text{CHCl}_3/\text{Et}_2\text{O}$ gave N- $\{[(R)-(2\text{-oxo-thiazolidin-4-yl})\text{carbonyl}]\}$ -L-leucyl-(1)-phosphotryptophan diethylester (3f) as a hygroscopic solid: 572 mg (73%); $[\alpha]_D^{22} = -89^\circ$ (1, methanol); IR (CHCl_3) 3333, 2958, 1678, 1513, 1339, 1260, 1026 cm^{-1} ; $^1\text{H-NMR}$ (CDCl_3): δ 0.69-0.92 [m, 6, $\text{CH}_2\text{CH}(\text{CH}_3)_2$], 1.08-1.65 [m, 9, $2\text{CH}_3\text{CH}_2\text{O}$ and $\text{CH}_2\text{CH}(\text{CH}_3)_2$], 2.92-3.47 (m, 4, CH_2S and $\text{bCH}_2 \text{Trp}^P$), 3.63-4.90 (m, 7, $2\text{CH}_3\text{CH}_2\text{O}$ and 3 aCH), 6.73-7.43 (m, 5, indole aromatics), 8.63 (s, 1, NH of indole). Calculated for $\text{C}_{24}\text{H}_{35}\text{N}_4\text{O}_6\text{PS} \cdot 1/2 \text{H}_2\text{O}$: C, 52.64; H, 6.63; N, 10.23. Found C, 52.66; H, 6.45; N, 10.03%.

N- $\{[(R)-(2\text{-oxo-thiazolidin-4-yl})\text{carbonyl}]\}$ -L-leucyl-(1)-phosphotryptophan diethylester (3f, 404 mg, 0.75 mmols), BSA (2.0 ml, 8.25 mmols) and TMSI (0.82 ml, 6.0 mmols) were reacted according to procedure B. Through treatment with cyclohexylamine (74 mg, 0.75 mmols) pure product is obtained (4f) as a hygroscopic solid: 312 mg (71%); $[\alpha]_D^{22} = -70^\circ$ (1, methanol); IR (KBr) 3285, 2936, 1641, 1532, 1141, 1047 cm^{-1} ; $^1\text{H-NMR}$ (DMSO-d_6): δ 0.75 [m,

6, $\text{CH}_2\text{CH}(\text{CH}_3)_2$], 1.00-2.00 [m, 13, $(\text{CH}_2)_5$ of cyclohexylamine and $\text{CH}_2\text{CH}(\text{CH}_3)_2$], 2.92 (m, 2, CHN of cyclohexylamine and 1H of $\text{bCH}_2 \text{Trp}^{\text{P}}$), 3.15-3.68 (m, 3, 1H of $\text{bCH}_2 \text{Trp}^{\text{P}}$ and CH_2S), 4.05-4.40 (m, 3, aCH Trp^{P} and aCH Leu superimposed over CHCH_2S), 6.85-7.68 (m, 5, indole aromatics), 8.05 (d, 1, $J = 8.6 \text{ Hz}$, NH of Trp^{P}), 8.78 (d, 1, $J = 8.6 \text{ Hz}$, NH Leu), 9.00 (bs, 1, NHCH_2S), 10.65 (s, 1, NH of indole). The assigning of the NH groups are interchangeable. Calculated for $\text{C}_{26}\text{H}_{40}\text{N}_5\text{O}_6\text{P} \cdot 1 \text{ H}_2\text{O}$ (cyclohexylamine salt): C, 52.02; H, 7.00; N, 11.67. Found C, 52.29; H, 7.07; N, 11.38%.

Preparation of N-Benzylloxycarbonyl-L-Pyroglutamyl-L-leucyl-(1)-phosphotryptophan cyclohexylamine salt (Compoundo 4g).

N-Benzylloxycarbonyl-L-pyroglutamyl-L-leucine (2g, 507 mg, 1.35 mmols) and (1)-phosphotryptophan diethylester (400 mg, 1.35 mmols) were reacted according to procedure A. The chromatography on silica gel ($\text{CHCl}_3/i\text{-PrOH}$ 95/5) of the raw product gave N-Benzylloxycarbonyl-L-pyroglutamyl-L-leucyl-(1)-phosphotryptophan diethylester (3g) in the form of foam: 466 mg (53%); $[\alpha]_{\text{D}}^{22} = -73^\circ$ (1, methanol); IR (KBr) 3287, 2957, 1787, 1654, 1552, 1232, 1028 cm^{-1} ; $^1\text{H-NMR}$ (MeOD): d 0.74-1.00 [m, 6, $\text{CH}_2\text{CH}(\text{CH}_3)_2$], 1.13-1.54 [m, 9, $2\text{CH}_3\text{CH}_2\text{O}$ and $\text{CH}_2\text{CH}(\text{CH}_3)_2$], 2.16-2.41 (m, 4, CH_2CH_2 of pGlu) 3.21-3.48 (m, 2, $\text{bCH}_2 \text{Trp}^{\text{P}}$), 4.00-4.91 (3m, 7, $2\text{CH}_3\text{CH}_2\text{O}$ and 3 aCH), 5.26 (s, 2, benzylic CH_2), 7.00-7.68 [m, 5, indole aromatics and 7.40 (s, 5, benzyl aromatics)]. Calculated for $\text{C}_{33}\text{H}_{43}\text{N}_4\text{O}_8\text{P}$: C, 60.54; H, 6.62; N, 8.56. Found. C, 60.03; H, 6.63; N, 8.33%.

N-benzylloxycarbonyl-L-pyroglutamyl-L-leucyl-(1)-phosphotryptophan diethylester (3g, 366 mg, 0.56 mmols), BSA (1.5 ml, 6.16 mmols) and TMSI (0.6 ml, 4.48 mmols) were reacted according to procedure B. For treatment with cyclohexylamine (55 mg, 0.56 mmols) pure product is obtained (4g) as an hygroscopic solid: 195 mg (62%); $[\alpha]_{\text{D}}^{22} = -72^\circ$ (1, NaOH 1N); IR (KBr) 3294, 2936, 1786,

1640, 1548, 1305, 1135, 1046 cm^{-1} ; $^1\text{H-NMR}$ (DMSO-d_6): δ 0.70 [m, 6, $\text{CH}_2\text{CH}(\text{CH}_3)_2$], 0.95-2.40 [m, 17, $(\text{CH}_2)_5$ cyclohexylamine, $\text{CH}_2\text{CH}(\text{CH}_3)_2$ and CH_2CH_2 of pGlu], 2.86 (m, 2, CHN of cyclohexylamine and 1 of b CH_2 Trp P), 3.25 (m, 1, 1 of b CH_2 Trp P), 4.00-4.30 (m, 2, aCH of Trp P and of the Leu), 4.71 (m, 1, aCH pGlu), 5.09 and 5.15 (A and B of an AB, 2, $J = 13$ Hz, PhCH_2O), 6.80-7.68 (m, 12, indole aromatics, benzyl aromatics and 2 NH), 8.86 (bs, 1, NH), 10.65 (s, 1, NH of the indole). Calculated for $\text{C}_{35}\text{H}_{48}\text{N}_5\text{O}_8\text{P} \cdot 1 \text{ H}_2\text{O}$ (cyclohexylamine salt): C, 58.67; H, 6.98; N, 9.78. Found C, 58.91; H, 6.97; N 9.33%.

Preparation of the L-pyroglutamyl-L-leucyl-(1)-phosphotryptophan salt of cyclohexylamine (Compound 4h).

A solution of N-benzyloxycarbonyl-L-pyroglutamyl-L-leucyl-(1)-phosphotryptophan cyclohexylamine salt (4f) (50 mg, 0.072 mmols) in EtOH/ H_2O 5:2 (7 ml) in presence of Pd/C 10% was kept 2 hours in a current of H_2 . After filtration on paper and removal of the solvent at reduced pressure, the product (4h) was obtained pure in the form of a pink hygroscopic solid: 34 mg (85%). $[\alpha]_{\text{D}}^{22} = -80^\circ$ (0.5, MeOH); IR (KBr) 3280, 2936, 1642, 1536, 1149, 1047 cm^{-1} ; $^1\text{H-NMR}$ (DMSO-d_6): δ 0.76 [m, 6, $\text{CH}_2\text{CH}(\text{CH}_3)_2$], 0.95-2.30 [m, 17, $(\text{CH}_2)_5$ cyclohexylamine, $\text{CH}_2\text{CH}(\text{CH}_3)_2$ and CH_2CH_2 of pGlu], 2.87 (bs, 2, CHN of cyclohexylamine and 1 of b CH_2 Trp P), 3.24 (m, 1, 1 of b CH_2 Trp P), 3.97-4.30 (m, 3, aCH of Trp P , of Leu and of pGlu), 6.80-7.60 (m, 5, indole aromatics), 7.91 (d, 1, $J = 8$ Hz, NH Trp P), 8.33 (s, 1, NH lactone), 8.50 (d, 1, $J = 7$ Hz, NH Leu), 10.66 (s, 1, NH of indole). Calculated for $\text{C}_{27}\text{H}_{42}\text{N}_5\text{O}_6\text{P} \cdot 3/2 \text{ H}_2\text{O}$ (cyclohexylamine salt): C, 54.86; H, 7.62; N, 11.85. Found C, 54.90; H, 7.55; N, 11.50%.

Example 4:

N[(furan-2-yl)-carbonyl-L-leucyl-phosphotryptophan Monobenzylester (Compound 10)].

Preparation of dibenzyl-1-hydroxyimine-2-(3-indolyl)ethanephosphonate (Compound 7).

To a suspension of indoleacetic acid (6, 5 g, 28.5

mmols) in anhydrous CH_2Cl_2 (100 ml) and anhydrous DMF (0.3 ml), cooled at 0°C was added dropwise, under stirring and in atmosphere of oxalyl nitrogen chloride (2.7 ml, 31.4 mmols) within a 30 minute time-span. The reaction mixture was refluxed for 30 minutes. At the end of such period the solvent was evaporated at reduced pressure and the oily residue containing the indoleacetic acid chloride, was dissolved in anhydrous CH_2Cl_2 (50 ml). To this solution, cooled at -18°C , was added dropwise, under stirring and in nitrogen atmosphere a solution of dibenzyl trimethylsilylphosphite in anhydrous CH_2Cl_2 (100 ml), obtained from dibenzylphosphite (6.33 ml, 28.5 mmols) and trimethylchlorosilane (5 ml, 39.5 mmols) in presence of triethylamine (Afarinkia K., Rees C.W., Cadogan J. I. G.; *Tetrahedron*, 1990, 46, 7175-7196), (4.38 ml, 31.4 mmols). After 1 hour the solvent was removed at reduced pressure and the oily residue dissolved in EtOH (35 ml) and pyridine (3.44 ml, 42.75 mmols). To this solution, cooled at -18°C , was added dropwise and under stirring a solution of hydroxylamine hydrochloride (2.57 g, 37.05 mmols) in MeOH (35 ml). After maintaining the reaction mixture for 12 hours at 4°C the solvent was removed at reduced pressure and the residue, dissolved in CHCl_3 (400 ml), was washed with H_2O (100 ml), saturated NaHCO_3 solution (100 ml) and saturated NaCl solution (100 ml). The organic phases were reunited and dried on Na_2SO_4 and the solvent was removed at reduced pressure. The purification of raw material through chromatography on silica gel ($\text{CH}_2\text{Cl}_2/i\text{-PrOH}$ 95/5) and crystallization through *sim*-dichloroethane provided the pure product (7), in the form of a solid white crystal: 5.74 g (46%); m.p. $130-1^\circ\text{C}$; IR (KBr): 3428, 3187, 1641, 1455, 1425, 1244, 1057 cm^{-1} ; $^1\text{H-NMR}$ (DMSO-d_6): d 3.77 (bs, 2, $\text{bCH}_2\text{ Trp}^{\text{P}}$), 4.70-4.90 (m, 4, $2\text{CH}_2\text{Ph}$), 6.80-7.60 (m, 15, aromatics), 10.60 (s, 1, NH of indole), 12.27 and 12.33 (two s, 1, C=N-OH).

Preparation of phosphotryptophan dibenzylester

oxalate (Compound 8).

To a solution of dibenzyl 1-hydroxyimine-2-(3-indolyl)ethanphosphonate (7, 2.61 g, 6.01 mmols) in EtOH/H₂O 13/1 (56 ml) and aqueous NH₃ at 25% (2.6 ml) was added an aluminium amalgam (3.60 g). After 1 hour the reaction mixture was filtrated on kieselguhr and the filtered substance was concentrated at reduced pressure. The raw product was dissolved in EtOAc (80 ml) and extracted with saturated NaHCO₃ solution (20 ml) and saturated NaCl solution (20 ml). After drying the organic phase on Na₂SO₄ the solvent was removed at reduced pressure. The raw product dissolved in EtOAc (10 ml), was additioned dropwise with a solution of oxalic acid (600 mg, 6.01 mmols) in EtOAc (10 ml). The pure product (8), separated as a solid hygroscopic crystal, was recovered by filtration: 2.087 g (68%). IR (CHCl₃): 3424, 2925, 1702, 1619, 1453, 1229, 1098, 998 cm⁻¹; ¹H-NMR (DMSO-d₆): δ 2.90-3.43 (m, 2, bCH₂ Trp^P), 3.60-4.03 (m, 1, aCH Trp^P), 4.70-5.13 (m, 4, 2CH₂Ph), 6.80-7.76 (m, 15, aromatics), 8.07 (bs, 1, NH of indole).

Preparation of N-[(Furan-2-yl)carbonyl]-L-leucyl-(1)-phosphotryptophan dibenzylester (Compound 9).

To a solution of N-[(furan-2-yl)carbonyl]-L-leucine (2a, 664 mg, 2.95 mmols) and N-methylmorpholine (0.32 ml, 2.95 mmols) in anhydrous THF (10 ml), cooled at -15°C was added dropwise, under stirring, an equivalent quantity of isobutylchloroformate (0.39 ml, 2.95 mmols). After 30 minutes a solution of dibenzyl-1-amino-2-(3-indolyl)ethanphosphonate was slowly added (8) in anhydrous THF (10 ml) maintaining the mixture under stirring at -15°C for 2 hours. The reaction mixture was diluted with CH₂Cl₂ (50 ml) and washed with HCl 1N (10 ml x 2), saturated NaHCO₃ solution (10 ml x 2) and saturated NaCl solution (10 ml). After drying the organic phase on Na₂SO₄ and removal of the solvent at reduced pressure, the raw product was purified through chromatography on silica gel (CH₂Cl₂/i-PrOH 95/5) obtaining by removing the

solvent at reduced pressure the pure product (9) in the form of white foam: 1.63 g (88%); IR (CHCl₃) 3477, 3419, 1660, 1594, 1512, 1248, 1011, 998 cm⁻¹; ¹H-NMR (CDCl₃): d 0.70 and 0.80 [two s, 6, CH₂CH(CH₃)₂], 1.10-1.71 [m, 3, CH₂CH(CH₃)₂], 3.10-3.33 (m, 2, bCH₂ Trp^P), 4.33-4.63 (m, 2, aCH Leu and aCH Trp^P), 4.77-4.97 (m, 4, CH₂Ph), 6.23-6.67 (two m, 2, amide NH), 6.76-7.47 (m, 18, aromatics), 8.07 (bs, 1, NH of indole).

Preparation of N-[(Furan-2-yl)carbonyl]-L-leucyl-(1)-phosphotryptophan monobenzyl-ester (Compound 10).

To a solution of N-[(furan-2-yl)carbonyl]-L-leucyl-(1)-phosphotryptophan dibenzylester (9) (100 mg, 0.159 mmols) in EtOH/H₂O 13/1 (1.5 ml) and aqueous NH₃ at 25% (0.07 ml) was added an aluminium amalgam (95 mg). After 4 days, the reaction mixture was filtered on kieselguhr and the filtrated substance was concentrated at reduced pressure. The raw reaction product was dissolved in CHCl₃ (10 ml) and extracted with NaOH 0.1N (5 ml x 2). The aqueous alkaline phases were acidified with HCl 1N (1.5 ml) and extracted with CHCl₃ (10 ml x 2). The organic phases were washed with saturated NaCl solution (5 ml), reunited and dried on Na₂SO₄. Through evaporation at reduced pressure of the solvent the pure product was obtained (10) in the form of white foam: 49 mg (58%); [α]_D²² = -24° (0.5, MeOH); IR (CHCl₃) 3477, 3414, 1649, 1595, 1516, 1011 cm⁻¹; ¹H-NMR (CDCl₃): d 0.70 and 0.80 [two s, 6, CH₂CH(CH₃)₂], 1.07-1.40 [m, 3, CH₂CH(CH₃)₂], 3.07-3.43 (m, 2, bCH₂ Trp^P), 4.40-4.73 (m, 2, aCH Leu and aCH Trp^P), 4.83-5.03 (m, 2, CH₂Ph), 6.07-6.40 (two m, 2, amide NH), 6.57-7.53 (m, 13, aromatics), 8.07 (bs, 1, NH of indole). Calculated for C₂₈H₃₂N₃O₆P.1 H₂O: C 60.48; H, 6.12; N, 7.56. Found C, 60.46; H, 5.99; N, 7.50%.

EXAMPLE 5:

Inhibition of Adamalysin II

The enzyme Adamalysin II, isolated from venom of the species *Crotalus Adamanteus* and obtained in extremely pure form from the laboratory of Prof. L.F. Kress

(Buffalo, NY, USA), was tested in its capacity of operating the scission of the fluorescent substratum 2-aminobenzoyl-ALA-GLY-LEU-ALA-4-nitrobenzylamide (of the Bachem firm). The production in time of fluorescent compounds was followed for 30 minutes, using as a detector a Perkin Elmer L 50B spectrofluorimeter, fixed at 320 nm for the excitation and at 420 nm for the emission.

Results (IC₅₀ expresses the concentration of the compound capable of reducing by 50% the scission of the fluorescent substratum):

Table I

COMPOUND	IC ₅₀
Compound n.3a	4 x 10 ⁻⁷ M
Compound n.3b	2,2 x 10 ⁻⁷ M
Compound n.3d	6,6 x 10 ⁻⁷ M
Compound n.3e	5,5 x 10 ⁻⁷ M
Compound n.4	1,0 x 10 ⁻⁶ M
Compound n.3f	1,0 x 10 ⁻⁶ M
Compound n.3c	2,2 x 10 ⁻⁵ M
Compound n.9	7,2 x 10 ⁻⁶ M

As can be seen in the reference table, all tested compounds result capable of inhibiting the enzyme, and some show remarkable power.

EXAMPLE 6:

Inhibition of the human enzyme Gelatinase A (MMP-2)

The synthesized compounds were also tested on the enzyme of human origin Gelatinase A, known also as MMP-2 (Matrix Metalloproteinase n. 2). The pure enzyme, extracted from human cultures and obtained from Prof. G. Murphy (Strangeways Labs., Cambridge, UK), was first activated with p-amino-mercuryacetate, and proteolytic activity was evidenced with the use of an artificial fluorescent substratum MCA-PRO-LEU-GLY-LEU-DPA-ALA-ARG-NH₂ (Strangeways Labs.), in spectrofluorimeter Perkin Elmer L 50B fixed at 328 nm for excitation and 393 nm for

emission. To test inhibitory activity, synthesized compounds were incubated for 3 hours at room temperature in the presence of the enzyme, before adding the substratum.

The results, expressed qualitatively, are shown in the following table:

Tabella II

COMPOUND	INHIBITION
Compound n.3a	Fair
Compoust n.3b	Good
Compound n.3d	None
Compound n.3e	Fair
Compound n.4	None
Compound n.3f	Fair
Compound n.3c	Good
Compound n.9	None

EXAMPLE 7:

Inhibition of human enzyme Collagenase from neutrophiles (MMP-8)

The new synthesized derivatives were also tested on another zinc-dependent metalloproteinase of human origin: the Collagenase from neutrophiles, also known as MMP-8 (Matrix Metalloproteinase n. 8). The pure enzyme extracted from human cell cultures and obtained from Prof. G. Murphy (Strangeways Labs., Cambridge, UK), was activated with p-aminomercuriacetate (2 hours at 37°C), and enzymatic activity was followed by the spectrofluorimeter in the same way as described in the previous chapter.

The results, expressed qualitatively, are shown in the following table:


Table III

COMPOUND	INHIBITION
Compound n.3a	Fair
Compound n.3b	Good
Compound n.3d	Fair

Compound n.3e	Fair
Compound n.4	None
Compound n.3f	Good
Compound n.3c	Good
Compound n.9	Fair


CLAIMS

1. Compounds with general formula:



in which R can be H, or CH₂-C₆H₅, and R' can be a saturated or aromatic ring of five or six members, of which at least one is not carbon and can be selected in the group including nitrogen, oxygen and sulphur.

2. Compounds according to claim 1, in which R' is selected from a group including:



3. A process for production of (1)-phosphotryptophan diester as the starting product in synthesizing the compounds claimed in claim 1, characterized by the fact of including as an essential operation the reduction of 1-hydroxyimine- 2-(3-indolyl) ethanphosphonate by adding an aluminium amalgam in presence of aqueous ammonia.

4. Compounds as defined in claim 1 or 2, for use as inhibitors of enzymatic activity of at least one of the snake zinc-dependent metalloproteinases extracted from snake venoms belonging to the families Crotalidae and Viperidae, also called hemorrhagines, and/or at least one of the zinc-dependent metalloproteinases of human origin whose active site presents a three-dimensional structure analogous to that of said snake metalloproteinases.

5. Compounds according to claim 4, in which said human metalloproteinases are ADAM.

6. Compounds according to claim 4, in which said metalloproteinase extracted from snake venom is Adamalysin II, and/or metalloproteinases of human origin are Collagenase and Gelatinase A.

7. Use of compounds as claimed in any of claims from 4 to 6, as pharmaceuticals for the therapeutic treatment in relation to all human pathologies in which the pathogenic mechanism or in which symptomatology has been shown to involve at least one zinc-dependent metalloproteinase.

8. Use of compounds according to claim 7, in which said pathology is tumoral growth and metastasization.

9. Use of compounds according to claim 7, in which said pathology is constituted by inflammatory diseases such as rheumatoid arthritis.

10. Use of compounds according to claim 7, in which said pathology is atherosclerosis.

11. Use of compounds according to claim 7, in which said pathology is multiple sclerosis.

12. Use of compounds according to claim 7, in which said pathology is Alzheimer's disease.

13. Use of compounds according to claim 7, in which said pathology is osteoporosis.

14. Use of compounds according to claim 7, in which said pathology is hypertension.

15. Pharmaceutical composition useful for therapy of human pathologies in whose pathogenic mechanism or in whose symptomatology an involvement of at least one zinc-dependent metalloproteinase has been proved, characterized by the fact of including as an active principle at least one of the compounds as claimed in claim 1, 2 or 4, and a pharmaceutically compatible vehicle.

16. Pharmaceutical compositions according to claim 15, in which said pathologies are comprised in the group including osteoporosis, Alzheimer's disease, multiple sclerosis, inflammatory diseases such as rheumatoid arthrytis, hypertension, atherosclerosis, and tumoral growth and metastasization.

17. Composition of matter characterized by the fact of including at least one compound as defined in claim 1 or 2.

18. Method to determine the therapeutic activity in mammals of compounds as defined in claim 1, comprising the steps of determining the level of activity of said compounds as inhibitors of zinc-dependent metalloproteinases extracted from venom of snakes belonging to the families Crotalidae and Viperidae, and then verifying the inhibitory activity of said compounds on metalloproteinases present in mammal organisms and which induce pathological situations, to recognize and produce an active drug useful in human and animal therapy.

19. Method according to claim 18, in which the zinc-dependent metalloproteinase extracted from snake venom is Adamalysin II.

20. Method according to claim 18 or 19, in which the metalloproteinases present in the organism of mammals are

Collagenase from neutrophils or Gelatinase A.

21. Compounds, methods to verify their properties, their use and pharmaceutical compounds which contain them, as previously described and exemplified.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 5/078, A61K 38/05, G01N 33/68	A3	(11) International Publication Number: WO 99/03878
		(43) International Publication Date: 28 January 1999 (28.01.99)
(21) International Application Number: PCT/IT98/00202 (22) International Filing Date: 17 July 1998 (17.07.98) (30) Priority Data: RM97A000441 17 July 1997 (17.07.97) IT (71) Applicants (<i>for all designated States except US</i>): POLIFARMA S.p.A. [IT/IT]; Via di Tor Sapienza, 138, I-00155 Roma (IT). CONSIGLIO NAZIONALE DELLE RICERCHE [-/IT]; Piazzale Aldo Moro 7, I-00185 Roma (IT). (72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): POLITI, Vincenzo [IT/IT]; Via Albano, 77, I-00179 Roma (IT). GAVUZZO, Enrico [IT/IT]; Via F. Turati, 155, I-00185 Roma (IT). GALLINA, Carlo [IT/IT]; Via Vigeveno, 10, I-00161 Roma (IT). DI STAZIO, Giovanni [IT/IT]; Via Clivo di Cinna, 221, I-00136 Roma (IT). D'ALESSIO, Silvana [IT/IT]; Piazza Marchisio, 245, I-00173 Roma (IT). SELLA, Antonio [IT/IT]; Via delle Petunie, 6, I-00171 Roma (IT). PIAZZA, Cinzia [IT/IT]; Via Forte Braschi, 84, I-00167 Roma (IT). GIORDANO, Cesare [IT/IT]; Via Gargallo, 6, I-00137 Roma (IT). GORINI, Barbara [IT/IT]; Piazza Vinci, 19, I-00139 Roma (IT). PANINI, Gabriella [IT/IT]; Via Lavagna, 7, I-00048 Nettuno (IT).		PAGLIALUNGA PARADISI, Mario [IT/IT]; Viale Marx, 319, I-00137 Roma (IT). CIRILLI, Maurizio [IT/IT]; Via P. Romano, 25, I-00169 Roma (IT). POCHETTI, Giorgio [IT/IT]; Via G. Antamoro, 100, I-00139 Roma (IT). MAZZA, Fernando [IT/IT]; Via E. Romagnoli, 3, I-00137 Roma (IT). (74) Agents: BAZZICHELLI, Alfredo et al.; Società Italiana Brevetti S.p.A., Piazza di Pietra, 39, I-00186 Roma (IT). (81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>In English translation (filed in Italian)</i> (88) Date of publication of the international search report: 1 April 1999 (01.04.99)
(54) Title: INHIBITORS OF METALLOPROTEINASES, THEIR THERAPEUTIC USE, AND PROCESS FOR THE PRODUCTION OF THE STARTING COMPOUND IN THEIR SYNTHESIS		
(57) Abstract Objects of the present invention are peptido-mimetic compounds having the capacity of acting as inhibitors of metalloproteinases produced by snake venom, and of other metalloproteinases of human origin which have been related with various pathologies in man, including tumoral growth and metastatization, atherosclerosis, multiple sclerosis, Alzheimer's disease, osteoporosis, hypertension, rheumatoid arthritis and other inflammatory diseases. Object of the present invention is also the procedure for the production of diethylester of (1)-phosphotryptophan, as starting product necessary to synthesize all compounds mentioned above.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IT 98/00202

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K5/078 A61K38/05 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>CIRILLI, M. ET AL: "2.ANG. X-ray structure of adamalysin II complexed with a peptide phosphonate inhibitor adopting a retro-binding mode"</p> <p>FEBS LETT. (1997), 418(3), 319-322 CODEN: FEBLAL; ISSN: 0014-5793, 1 December 1997, XP002089575</p> <p>see page 319, right-hand column, last paragraph - page 320, left-hand column, paragraph 1</p> <p>see page 321, right-hand column, last paragraph - page 322, left-hand column, paragraph 1</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1-7, 15-21

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

11 January 1999

Date of mailing of the international search report

25/01/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Fuhr, C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IT 98/00202

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>CALCAGNI, ANNA ET AL: "Inhibitors of zinc-dependent metalloproteinases: Synthesis and activity of N-(2-furoyl)-(Z)-.alpha.,.beta.-didehydro-L-tryptophan" FARMACO (1993), 48(9), 1271-7 CODEN: FRMCE8, 1993, XP002089576 see page 1273, paragraph 2 - paragraph 3; table I see page 1275, paragraph 1 - paragraph 3 ----</p>	1-7, 15-21
A	<p>EP 0 401 963 A (BEECHAM GROUP PLC) 12 December 1990 see description 3 see page 3, line 27 - page 4, line 11; claims; example 1 ----</p>	1,7, 15-17,21
A	<p>EP 0 758 021 A (POLIFARMA SPA) 12 February 1997 see claims; examples ----</p>	1,7, 15-17,21
A	<p>WO 92 06108 A (POLIFARMA SPA) 16 April 1992 see claims; examples -----</p>	1,7, 15-17,21

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IT 98/00202

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 7-14 and 21
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IT 98/00202

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0401963 A	12-12-1990	AU 618669 B	02-01-1992
		AU 5315890 A	18-10-1990
		CA 2014375 A	13-10-1990
		JP 3063294 A	19-03-1991
		PT 93724 A	20-11-1990
		US 5212163 A	18-05-1993
EP 0758021 A	12-02-1997	IT RM950557 A	07-02-1997
		JP 9136841 A	27-05-1997
		US 5846755 A	08-12-1998
WO 9206108 A	16-04-1992	IT 1242002 B	02-02-1994
		AU 640534 B	26-08-1993
		AU 8715091 A	28-04-1992
		CA 2070169 A	04-04-1992
		DE 69120247 D	18-07-1996
		DE 69120247 T	23-01-1997
		EP 0503044 A	16-09-1992
		ES 2089234 T	01-10-1996
		JP 2502868 B	29-05-1996
		JP 4506083 T	22-10-1992
		US 5504071 A	02-04-1996
		US 5736518 A	07-04-1998